# 1. Financial Performance ## A. Key Figures * **Profitability:** **₹15.5 Cr** Standalone Net Loss in Q3 (vs. ₹2.9 Cr loss YoY) * **EBITDA Margin:** **28%** Clinic-level pre-IndAS * **Liquidity & Debt:** **₹143.72 Cr** Total Debt · **₹124 Cr** Net Debt · **₹18 Cr** Cash Balance ## B. Revenue & Margin Dynamics * **Top-line Momentum:** Achieved mid-single-digit standalone revenue growth, underpinned by high-single-digit expansion in the core Clinic segment. [2, 4] * **Operating Leverage Gap:** Incremental revenue gains failed to translate into expected EBITDA flow-through, highlighting a disconnect between top-line scaling and bottom-line conversion. * **Profitability Targets:** Management is targeting clinic-level margins exceeding **30%** as the critical threshold to achieve company-wide EBITDA and PAT positivity. ## C. Capital Structure & Exceptional Items * **Funding Strategy:** Board approved **₹18 Cr** in additional borrowing to secure working capital and finance the rollout of new clinic locations. * **Non-Recurring Impact:** Quarterly losses were significantly widened by a **₹4.6 Cr** exceptional charge related to the sale and impairment of investments. --- # 2. Service & Product Performance ## A. Key Figures * **Revenue Growth:** **9%** Services segment · **8%** Clinic product business · **Flat** Overall product revenue * **Category Growth:** **28%** Anti-aging (highest specific rate) * **Innovation Contribution:** **5%** New product development · **7%** New service development ## B. Category & Innovation Drivers * **Service Momentum:** Robust top-line growth in services fueled by high demand in body contouring, hair care, and brightening categories. * **Anti-Aging Outperformance:** Significant double-digit acceleration in anti-aging treatments represents the fastest-growing vertical this quarter. * **R&D Yield:** Innovation remains a critical pillar, with new service and product developments collectively contributing **12%** to total collections. ## C. Product Mix & Profitability * **Margin Compression:** EBITDA growth lagged revenue due to a mix shift toward high-consumable categories (anti-aging/body contouring) which carry **lower gross margins**. * **Segment Divergence:** While the internal clinic product business saw high single-digit growth, the total product revenue was stagnant compared to the prior year. ## D. Strategic Collaborations * **Marico Partnership:** The collaboration focused on the product segment contributed approximately **Rs. 2 crores** in sales for the current quarter. --- # 3. Clinic & Operating Metrics ## A. Key Figures * **New Clinic Openings:** **3** YTD FY25 · **4** Total FY25 Target * **Clinic Refresh Program:** **7** Relocations YTD · **13** Renovations YTD (including **6** in Q3) * **Loyalty Contribution:** **>90%** of total collections · **14%** YoY growth * **Net Promoter Score (NPS):** **88** ## B. Expansion & Renovation * **Accelerating Footprint:** Following a multi-year hiatus, the company is scaling its physical presence with a new launch in Chennai and plans to significantly increase the pace of openings in upcoming quarters. * **Infrastructure Modernization:** The "Clinic Refresh" initiative remains a core focus, with extensive renovations and strategic relocations completed across key hubs including Hyderabad, Pune, and Noida to enhance service delivery. ## C. Loyalty & Customer Experience * **Dominant Loyalty Retention:** The Smiles Loyalty program continues to be the primary revenue driver, showing double-digit collection growth and representing the vast majority of the business mix. * **Service Quality:** High customer satisfaction levels were maintained throughout the quarter, as evidenced by a robust NPS. ## D. Marketing & Operating Costs * **Strategic Spend:** Management has intentionally ramped up marketing investment to catalyze collection growth and top-line revenue, contributing to a higher operating cost base. --- # 4. Technology & Innovation ## A. Key Figures * **Category Growth:** **22%** Body & Hair Care services YoY * **Asset Deployment:** **18** New dermatology machines ## B. Diagnostic Tools & AI * **Proprietary AI Launch:** Introduced the **Clear AI app**, a skin health analysis tool leveraging a database of **thousands of Indian customer references** for personalized acne and aging diagnoses. * **Service Synergy:** Robust double-digit growth in hair care was catalyzed by the integration of advanced diagnostic tools and redesigned customer journeys. ## C. Equipment & Digital Automation * **Efficacy Enhancements:** Strategic investment in specialized machinery focused on high-demand treatments including brightening, acne, and laser hair reduction. * **Operational Streamlining:** Deployment of **WhatsApp and Web bots** via new marketing automation tools to optimize the appointment booking lifecycle and customer UX. --- # 5. Capital Strategy ## A. Key Figures * **Exceptional Gain:** **₹113.5 Cr** from divestment of Middle East operations * **Rights Issue Timeline:** **65 to 75 working days** estimated duration post-legislation ## B. Rights Issue & Promoter Funding * **Regulatory Dependency:** The planned rights issue is currently on hold pending **SEBI amendments** intended to streamline the issuance process. * **Interim Liquidity:** Promoters are providing bridge funding to sustain operational momentum and expansion until the equity raise is finalized. * **Strategic Pivot:** Management intends to shift to a more aggressive growth posture immediately following the capital infusion. ## C. Asset Divestment * **Portfolio Optimization:** Successfully exited the Middle East market via the sale of FZE and DMCC entities in mid-to-late 2024. * **Profitability Impact:** The divestment resulted in a significant recognized gain, categorized as an exceptional item for the nine months ending December 31, 2024. ## D. Market Scoping * **Data-Driven Expansion:** Completed a comprehensive scoping exercise utilizing external consultants and proprietary tech tools to identify high-potential catchment areas. * **Strategic Focus:** Future footprint growth is strictly prioritized around **profitable expansion** rather than purely volume-based scaling. --- # 7. Guidance & Outlook ## A. Growth Strategy * **Dual-Pronged Expansion:** Management plans to sustain momentum through a strategic combination of organic like-for-like growth and a revitalized clinic expansion program. * **Phased Implementation:** The expansion strategy will be executed via incremental updates on a quarter-to-quarter basis, contingent upon funding availability. * **Guidance Pause:** While expansion remains a core priority, specific targets for the **number of clinic openings for FY '26** have been withheld pending further implementation.